



Oncocyte to Report Third Quarter 2018 Financial Results on November 13, 2018

Nov 06, 2018

ALAMEDA, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the third quarter ended September 30, 2018, on Tuesday, November 13, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, November 13, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all callers, please refer to Conference ID 13684100. To access the live webcast, go to the investor relations section on the Company's website, <http://investors.oncoyte.com/events-and-presentations>.

A replay of the conference call will be available for ten business days beginning about two hours after the conclusion of the live call, by calling 844-512-2921 toll-free (from U.S./Canada); international callers dial 412-317-6671. Use the Conference ID 13684100. Additionally, the archived webcast will be available at <http://investors.oncoyte.com/events-and-presentations>.

About OncoCyte Corporation

OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine ("liquid biopsy") diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients' quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy procedures. OncoCyte's is focusing its efforts on developing DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic and protein molecular markers to detect the presence of lung cancer. OncoCyte also plans to conduct research to identify additional molecular markers, acquire or license markers and related technology, and develop cancer tests based on those markers.

Contact

Bob Yedid
LifeSci Advisors, LLC
bob@lifesciadvisors.com
646-597-6989



Source: OncoCyte Corporation

